Skip to content

XenoPort Inc’s psoriasis drug showed high rates of gastrointestinal-related side effects, overshadowing its success in a mid-stage study

(Reuters) – XenoPort Inc’s psoriasis drug showed high rates of gastrointestinal-related side effects, overshadowing its success in a mid-stage study. During the trial of the drug, XP23829, in patients suffering from the chronic skin disease, adverse events related to diarrhea were 22-40 percent in the drug group, compared with 15 percent in the placebo group, the company said. XenoPort’s psoriasis drug shows higher side effects; shares fall. XenoPort Inc’s psoriasis drug showed high rates of gastrointestinal-related side effects, overshadowing its success in a mid-stage study. (Reuters) – XenoPort Inc’s psoriasis drug showed high rates of gastrointestinal-related side effects, overshadowing its success in a mid-stage study. Original Article: XenoPort’s psoriasis drug shows higher side effects; shares fall.

XenoPort Inc's psoriasis drug showed high rates of gastrointestinal-related side effects, overshadowing its success in a mid-stage study 2XenoPort’s psoriasis drug shows higher side effects; shares fall. XenoPort Inc’s psoriasis drug showed high rates of gastrointestinal-related side effects, overshadowing its success in a mid-stage study. XenoPort’s psoriasis drug shows higher side effects; shares fall Thumbnail. September 15, 2015 – 12:04 PM Reuters. (Reuters) – XenoPort Inc’s psoriasis drug showed high rates of gastrointestinal-related side effects, overshadowing its success in a mid-stage study. Read More. Tags: Xenoport Inc – Reuters – psoriasis. (Reuters) – XenoPort Inc’s psoriasis drug showed high rates of gastrointestinal-related side effects, overshadowing its success in a mid-stage study.

King World News

Xenoport’s Psoriasis Drug Shows Higher Side Effects; Shares Fall